Sunshine Biopharma closes $6 million public offering
Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash
Sunshine Biopharma (SBFM) closed a public offering raising roughly $6 million in gross proceeds on October 9, 2026. The deal comprised common and pre-funded units, each paired with Series D warrants, priced at $0.55 and $0.54999. Proceeds fund general corporate purposes, working capital and drug development. The raise dilutes existing shareholders while extending the company's cash runway.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.